

Inrebic (fedratinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.

Inrebic (fedratinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
<input type="checkbox"/> Myelofibrosis <input type="checkbox"/> Other diagnosis: _____ ICD-10 _____		
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
Clinical Information: Will patient use Inrebic(fedratinib) Ojjaara(momelotinib) in combination with Vonjo(pacritinib), Ojjaara(momelotinib), or Jakafi(ruxolitinib)? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i>		
Does the patient have a diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia)? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation</i>		
Does the patient have constitutional symptoms? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation</i>		
Does have a hemoglobin level less than 10 g/dL? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation</i>		
Does the patient have a WBC count greater than 25 x 10⁹/ L ? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation</i>		
Does the patient have blood blasts on a peripheral smear equaling 1% or greater? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation</i>		
Does the patient have an enlarged spleen at least 5cm below the costal margin? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation</i>		
Has the patient undergone a bone marrow biopsy including semiquantitative evaluation of fibrosis, which showed megakaryocytic proliferation and atypia accompanied by either reticulin and/or collagen fibrosis grades 2 or 3? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation</i>		
Does the patient have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (is ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours)? <input type="checkbox"/> Yes <input type="checkbox"/> No		
Does the patient have an absolute neutrophil count (ANC) equaling at least 1.0 x 10⁹/ L? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation</i>		
Does the patient have a platelet count of at least 50 x 10⁹/ L? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation</i>		

Inrebic (fedratinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

Has the patient received prior treatment with a JAK2 inhibitor (such as ruxolitinib/ Jakafi® or fedratinib/ Inrebic®)?
 Yes No *Please submit documentation*

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

***Please note:** Not all drugs/diagnoses are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP - 4201

P.O. Box 64811

St. Paul, MN 55164-0811